Oral ( DrugBank: - )

2 diseases

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	194
271	Ankylosing spondylitis	21

46. Malignant rheumatoid arthritis

Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

diseases per page:

Showing 1 to 10 of 194 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05238896 (ClinicalTrials.gov)	March 1, 2022	4/1/2022	BARIcitinib Cognitive Emotional and Neural signaTuRE	BARIcitinib Cognitive Emotional and Neural signaTuRE (BARICENTRE)	Rheumatoid Arthritis	Drug: Baricitinib Oral Tablet [Olumiant];Drug: Placebo	Assistance Publique - Hôpitaux de Paris	NULL	Not yet recruiting	18 Years	75 Years	All	80	Phase 4	France
2	NCT04844008 (ClinicalTrials.gov)	October 5, 2021	30/3/2021	Do Nanobubbles Improve Joint Hypoxia?	An Investigation of Whether Orally Delivered Nanobubbles Have a Physiological Effect on Joint Hypoxi ...	Rheumatoid Arthritis;Psoriatic Arthritis	Dietary Supplement: Nanobubble drink	University of Oxford	NULL	Recruiting	18 Years	N/A	All	20	N/A	United Kingdom
3	JPRN-UMIN000043547	2021/03/08	08/03/2021	Examination of structural remission and reduction of drug free of filgotinib in rheumatoid arthritis ...	Examination of structural remission and reduction of drug free of filgotinib in rheumatoid arthritis ...	Rheumatoid Arthritis	60 weeks Oral administration of 200mg filgotinib daily	DeparShinshu University School of Medicine	NULL	Recruiting	20years-old	100years-old	Male and Female	100	Not selected	Japan
4	EUCTR2020-003955-14-DE (EUCTR)	21/12/2020	04/11/2020	A Placebo controlled trial in adult patients with active rheumatoid arthritis with inadequate (parti ...	A Randomized, Double-blind, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study of the Eff ...	Active Rheumatoid Arthritis MedDRA version: 23.1;Level: PT;Classification code 10039073;Term: Rheuma ...	Product Code: AMT-101 Other descriptive name: AMT-101	Applied Molecular Transport Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 2	Germany
5	NCT04649697 (ClinicalTrials.gov)	December 1, 2020	26/10/2020	Rebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced OralUlc ...	Evaluation of Topical Rebamipide Versus Topical Clobetasol in Management of Methotrexate-Induced Ora ...	Rheumatoid Arthritis	Drug: Rebamipide;Drug: Nanoparticulated Rebamipide;Drug: Clobetasol Propionate	Cairo University	NULL	Not yet recruiting	20 Years	70 Years	All	39	Phase 3	NULL
6	EUCTR2020-000658-83-BG (EUCTR)	21/10/2020	07/10/2020	A study evaluating the effects of GLPG3970 given as an oraltreatment for 6 weeks in adults with mode ...	A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerabili ...	Rheumatoid arthritis MedDRA version: 23.1;Level: PT;Classification code 10039073;Term: Rheumatoid ar ...	Product Name: GLPG3970 Product Code: G1567970 INN or Proposed INN: Not applicable Other descriptive nam ...	Galapagos NV	NULL	Not Recruiting			Female: yes Male: yes	25	Phase 2	Poland;Ukraine;Georgia;Bulgaria
7	NCT04577781 (ClinicalTrials.gov)	October 12, 2020	30/9/2020	A Study Evaluating the Effects of GLPG3970 Given as an OralTreatment for 6 Weeks in Adults With Mode ...	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerabili ...	Rheumatoid Arthritis	Drug: GLPG3970;Drug: Placebo	Galapagos NV	NULL	Completed	18 Years	64 Years	All	28	Phase 2	Bulgaria;Georgia;Poland;Ukraine
8	NCT04247815 (ClinicalTrials.gov)	March 16, 2020	16/1/2020	Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA	A Phase 2a, Randomized, Investigator and Patient-blind, Sponsor-unblinded, Parallel Group, Placebo-c ...	Rheumatoid Arthritis	Drug: ATI-450;Drug: Placebo oral tablet;Drug: Methotrexate	Aclaris Therapeutics, Inc.	NULL	Completed	18 Years	70 Years	All	19	Phase 2	United States
9	ChiCTR1900027855	2019-11-29	2019-11-30	Pharmacokinetics of CYP2C9 * 3 homozygous mutant subjects in a single oral meloxicam tablet	Pharmacokinetics of CYP2C9 * 3 homozygous mutant subjects in a single oral meloxicam tablet	Osteoarthritis, rheumatoid arthritis	Case:Meloxicam 15mg;	Center for Clinical Pharmacology, the Third Xiangya Hospital, Central South University	NULL	Pending	18	45	Male	Case:1;	Phase 1	China
10	ChiCTR1900026257	2019-09-28	2019-09-28	A Randomized, Double-Blind Clinical Trial for Effect of Wisconsin Ginseng (Panax quinquefolius) in I ...	Efficacy, dose comparison, and safety of Wisconsin Ginseng (Panax quinquefolius) in patients with rh ...	Rheumatoid arthritis (RA)	High-dose experimental group :6000mg Wisconsin ginseng (Panax quinquefolius) herb intervention: 3000 ...	Zhejiang Provincal Hospital of TCM	NULL	Pending	18	70	Both	High-dose experimental group :30;Low-dose experimental group:30;Control group :30;	Phase 2	China

First Previous1 2 3 4 5…20Next Last

271. Ankylosing spondylitis

Clinical trials : 563 / Drugs : 372 - (DrugBank : 72) / Drug target genes : 41 - Drug target pathways : 145

diseases per page:

Showing 1 to 10 of 21 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100044284	2021-03-09	2021-03-14	Study on the effect of ginger with different thickness on the treatment of ankylosing spondylitis	Effect of Fuyang and Dumoxibustion on Ankylosing Spondylitis of Kidney-Yang Deficiency and on TNF-a ...	Ankylosing spondylitis	The control group:Celecoxib 20mg once daily;Ginger tube moxibustion group:Oralcelecoxib 20mg once a ...	Affiliated Hospital of Nanjing University of Chinese Medicine	NULL	Recruiting	18	60	Male	The control group:20;Ginger tube moxibustion group:20;Thick ginger du moxibustion group:20;		China
2	ChiCTR2000034142	2019-04-01	2020-06-26	Study on TCM Syndrome Classification and Diagnosis and Treatment of Ankylosing Spondylitis by Metabo ...	Study on TCM Syndrome Classification and Diagnosis and Treatment of Ankylosing Spondylitis by Metabo ...	Ankylosing spondylitis	Experimental group:Take Chinese medicine preparation Wen-Shen Juan-Bi-Tang orally;Experimental group ...	Jiangsu Province Hospital of TCM	NULL	Pending	25	70	Both	Experimental group:40;Experimental group 2:40;NSAID:40;	N/A	China
3	NCT03329885 (ClinicalTrials.gov)	November 2, 2017	31/10/2017	A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients ...	A Double-Blind Randomized Placebo-Controlled Single and Multiple Ascending Doses Study of the Safety ...	Rheumatoid Arthritis;Psoriasis;Ankylosing Spondylitis;Inflammatory Bowel Diseases;Nonalcoholic Steat ...	Drug: BMS-986251;Other: Placebo	Bristol-Myers Squibb	NULL	Terminated	18 Years	70 Years	All	38	Phase 1/Phase 2	Netherlands
4	NCT03140657 (ClinicalTrials.gov)	April 29, 2017	28/4/2017	The Effects of Nanocurcumin on Treg Cells and Th17 Cells Responses in Ankylosing Spondylitis Patient ...	The Effects of OralNanocurcumin on Expression Levels of microRNAs and Treg Cells and Th17 Cells Deve ...	Ankylosing Spondylitis	Drug: Nanocurcumin;Drug: Placebo	Tabriz University of Medical Sciences	NULL	Completed	23 Years	46 Years	All	24	Phase 2	Iran, Islamic Republic of
5	NCT03117270 (ClinicalTrials.gov)	March 7, 2017	30/3/2017	A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis	A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Efficacy a ...	Ankylosing Spondylitis	Drug: filgotinib;Drug: Placebo Oral Tablet	Galapagos NV	NULL	Completed	18 Years	N/A	All	116	Phase 2	Belgium;Bulgaria;Czechia;Estonia;Poland;Spain;Ukraine
6	EUCTR2011-001555-37-EE (EUCTR)	19/04/2013	19/03/2013	Phase 3 study to evaluate safety and effectiveness of oralApremilast (CC-10004) in patients with ank ...	A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evalua ...	Ankylosing spondylitis (AS) MedDRA version: 18.1;Level: PT;Classification code 10002556;Term: Ankylo ...	Product Name: Apremilast Product Code: CC-10004 INN or Proposed INN: Apremilast Product Name: Apremilas ...	Celgene Corporation	NULL	Not Recruiting			Female: yes Male: yes	456	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	United States;Estonia;Slovakia;Spain;Austria;Russian Federation;United Kingdom;France;Hungary;Czech ...
7	EUCTR2011-001555-37-NL (EUCTR)	05/12/2012	15/05/2012	Phase 3 study to evaluate safety and effectiveness of oralApremilast (CC-10004) in patients with ank ...	A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evalua ...	Ankylosing spondylitis (AS) MedDRA version: 14.1;Level: PT;Classification code 10002556;Term: Ankylo ...	Product Name: Apremilast Product Code: CC-10004 INN or Proposed INN: Apremilast Product Name: Apremilas ...	Celgene Corporation	NULL	Not Recruiting			Female: yes Male: yes	456	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	United States;Estonia;Slovakia;Spain;Austria;Russian Federation;United Kingdom;France;Hungary;Czech ...
8	EUCTR2011-001555-37-BG (EUCTR)	14/11/2012	14/08/2012	Phase 3 study to evaluate safety and effectiveness of oralApremilast (CC-10004) in patients with ank ...	A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evalua ...	Ankylosing spondylitis (AS) MedDRA version: 20.0;Level: PT;Classification code 10002556;Term: Ankylo ...	Product Name: Apremilast Product Code: CC-10004 INN or Proposed INN: Apremilast Product Name: Apremilas ...	Celgene Corporation	NULL	Not Recruiting			Female: yes Male: yes	456	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	United States;Estonia;Slovakia;Spain;Austria;Russian Federation;United Kingdom;France;Hungary;Czech ...
9	EUCTR2011-001555-37-DE (EUCTR)	20/09/2012	08/05/2012	Phase 3 study to evaluate safety and effectiveness of oralApremilast (CC-10004) in patients with ank ...	A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evalua ...	Ankylosing spondylitis (AS) MedDRA version: 18.0;Level: PT;Classification code 10002556;Term: Ankylo ...	Product Name: Apremilast Product Code: CC-10004 INN or Proposed INN: Apremilast Product Name: Apremilas ...	Celgene Corporation	NULL	Not Recruiting			Female: yes Male: yes	456	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	United States;Estonia;Slovakia;Spain;Austria;Russian Federation;United Kingdom;France;Hungary;Czech ...
10	EUCTR2011-001555-37-GB (EUCTR)	04/09/2012	16/04/2012	Phase 3 study to evaluate safety and effectiveness of oralApremilast (CC-10004) in patients with ank ...	A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evalua ...	Ankylosing spondylitis (AS) MedDRA version: 20.0;Level: PT;Classification code 10002556;Term: Ankylo ...	Product Name: Apremilast Product Code: CC-10004 INN or Proposed INN: Apremilast Product Name: Apremilas ...	Celgene Corporation	NULL	Not Recruiting			Female: yes Male: yes	456	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	United States;Estonia;Slovakia;Spain;Austria;Russian Federation;United Kingdom;France;Hungary;Czech ...

First Previous1 2 3Next Last